Triptan use in general practice: A French pharmacoepidemiological study;Etude pharmacoépidémiologique Française de l'utilisation des triptans en médecine générale

Therapie

Volumn 59, Issue 5, 2004, Pages 533-539

  Sénard, Jean Michel ^a   Nachit Ouinekh, Fatima ^b   Becq, Jean Philippe ^c   Chastan, Georges ^c   Fabre, Nelly ^d   El Hasnaoui, Abdelkader ^b  

^a INSERM   (France)

^b GLAXOSMITHKLINE   (France)

^c Capitole Santé   (France)

^d CHU RANGUEIL   (France)

Author keywords

General practice; Migraine; Pharmacoepidemiological study; Triptans

Indexed keywords

AMITRIPTYLINE; ANTIMIGRAINE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIHYDROERGOTAMINE; ERGOTAMINE TARTRATE; FLUNARIZINE; INDORAMIN; METHYSERGIDE; OXETORONE; PIZOTIFEN; SEROTONIN AGONIST; SEROTONIN ANTAGONIST; TRICYCLIC ANTIDEPRESSANT AGENT; TRIPTAN; UNCLASSIFIED DRUG; VERAPAMIL;

ADULT; ANAMNESIS; CONFERENCE PAPER; DISABILITY; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERABILITY; DRUG USE; FEMALE; FRANCE; GENERAL PRACTICE; GENERAL PRACTITIONER; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIGRAINE; PHARMACOEPIDEMIOLOGY; POPULATION; PRIORITY JOURNAL; QUALITY OF LIFE; RECURRENT DISEASE;

EID: 11144239951     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: 10.2515/therapie:2004091     Document Type: Conference Paper

References (21)

1. Henry P, Michel PH, Brochet B, et al. A nationwide survey of migraine in France: prevalence and clinical features in adults. Cephalalgia 1992; 12: 229-37
2. Henry P, Auray JP, Gaudin AF, et al. Prevalence and clinical characteristics of migraine in France. Neurology 2002; 59: 232-7
3. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988; 8 Suppl. 7: 1-96
4. Lipton RB, Stewart WF, Von Korff M. The burden of migraine: a review of cost to society. Pharmacoeconomics 1994; 6: 215-21
5. Rasmussen BK. Epidemiology and socio-economic impact of headache. Cephalalgia 1999; 19 Suppl. 25: 20-3
6. Lipton RB, Sher AI, Kolodner K, et al. Migraine in the United States: epidemiology and patterns of health care use. Neurology 2002; 58: 885-94
7. Osterhaus JT, Townsend RJ. Measuring the functional status and well being of patients with migraine headache. Headache 1994; 34 (6): 337-43
8. Michel P, Dartigues JF, Lindoulsi A, et al. Loss of productivity and quality of life in migraine sufferers among French workers: results from the Gazel cohort. Headache 1996; 37: 71-8
9. Expertise collective INSERM. La migraine : connaissances descriptives, traitements et prévention. Paris : Editions de l'INSERM, 1998: 39-57
10. Lantéri-Minet M, Auray JP, El Hasnaoui A, et al. Prevalence and description of chronic daily headache in the general population in France. Pain 2003 ; 102 (1-2): 143-9
11. 1D receptor agonists in migraine. CNS Drugs 1998; 10: 271-86
12. De Vries G. Triptans. Emerg Drugs 1999; 4: 36-45
13. Ferrari MD, Haan J. Drug treatment of migraine attacks. In: Goadsby PJ, Silberstein SD, editors. Headache. Boston: Butterworth-Heineman, 1997: 117-31
14. Schoenen J. Acute migraine therapy: the newer drugs. Curr Opin Neurol 1997; 10: 237-43
15. ANAES. Prise en charge diagnostique et thérapeutique de la migraine chez l'adulte et chez l'enfant : aspects cliniques et économiques. Recommandations, 2002 [online]. Available from URL: http://www.anaes.fr
16. El Hasnaoui A, Vray M, Richard A, et al. Assessing the severity of migraine: development of the MigSev scale. Headache 2003; 43 (6): 628-35
17. Richard A, Henry P, Chazot GY, et al. Qualité de vie et migraine, validation du questionnaire QVM en consultation hospitalière et en médecine générale. Thérapie 1993; 48: 89-96
18. Aguzzoli F, Le Fur P, Sermet C. Clientèle et motifs de recours en médecine libérale. CREDES no 1008, 1994/03: 166
19. Perry CM, Markham A. Sumatriptan, an updated review of its use in migraine. Drugs 1998; 55 (6): 889-922
20. Lucas C, Lantéri-Minet M, Leroy L. Framig 99-111 : comportements thérapeutiques des migraineux. La lettre du neurologue 2000; 4 Suppl. 5: 14-6
21. Lucas C, Auray JP, Gaudin AF, et al. Use and misuse of triptans in France: data from the GRIM2000 population survey. Cephalalgia 2004; 24 (3): 197-205